Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.62 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2983534 | 0.93 | PTGER4 (0.71) | PTGER4 | |
| SCHEMBL5350571 | 0.87 | PTGER4 (0.75) | PTGER4 | |
| SCHEMBL13206259 | 0.86 | PTGER4 (0.62) | PTGER4 | |
| SCHEMBL2987651 | 0.86 | FFAR1 (0.46) | PTGER4GPR34 | |
| SCHEMBL2983532 | 0.85 | PTGER4 (0.63) | PTGER4 | |
| SCHEMBL2981143 | 0.83 | PTGER4 (0.67) | PTGER4 | |
| SCHEMBL2981280 | 0.83 | PTGER4 (0.57) | PTGER4 | |
| SCHEMBL2982650 | 0.82 | PTGER4 (0.54) | PTGER4 | |
| SCHEMBL2987432 | 0.80 | PTGER4 (0.62) | PTGER4 | |
| SCHEMBL2980312 | 0.80 | PTGER4 (0.49) | PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786161-B2 | Carboxylic acid derivatives and pharmaceutical agent comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-31 | — | — | US | claimed |
| US-20090318703-A1 | CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD (JP) | 2009-12-24 | — | — | US | claimed |
| US-20060258728-A1 | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-11-16 | — | — | US | claimed |
| EP-1431267-A1 | CARBOXYLIC ACID DERIVATIVE COMPOUNDS AND DRUGS COMPRISING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-23 | — | — | EP | claimed |
| US-7786161-B2 | Carboxylic acid derivatives and pharmaceutical agent comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-31 | — | — | US | disclosed |
| US-7786161-B2 | Carboxylic acid derivatives and pharmaceutical agent comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-31 | — | — | US | disclosed |
| US-20090318703-A1 | CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318703-A1 | CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD (JP) | 2009-12-24 | — | — | US | disclosed |
| US-7491748-B2 | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| US-7491748-B2 | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| US-20060258728-A1 | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
| EP-1431267-A1 | CARBOXYLIC ACID DERIVATIVE COMPOUNDS AND DRUGS COMPRISING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318703-A1 | CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | PTGER2, PTGER4, PTGER1 | PTGER4 2/4885GPR34 66/4885PDCD1 3845/4885 |
| US-20060258728-A1 | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | PTGER2, PTGER4, PTGER1 | PTGER4 2/4885GPR34 78/4885PDCD1 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.